Atara Biotherapeutics Director Brian Cherry Buys 104,166 Shares

What Happened Brian N. Cherry, a director of Atara Biotherapeutics, purchased 104,166 shares of the company on September 4, 2026 at $9.60 per share, for a total purchase price of $999,994. This was a purchase (insider buy), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction date and price: 2026-09-04; 104,166 shares at $9.60 each.
• Total value: $999,994 (approximately $1.0 million).
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: The filing states the shares were purchased from the issuer through its sales agent pursuant to a Sales Agreement dated November 1, 2023 between the issuer and TD Securities (USA) LLC (see footnote F1).
• Filing timeliness: Reported on 2026-09-04 (same date as the transaction), with Exhibit 24 (Power of Attorney) listed.

Context This was a direct purchase from the issuer via its sales agent under a sales agreement (not a gift or option exercise). Insider purchases can signal confidence, but a single transaction should be considered alongside other insider activity, company fundamentals, and market conditions. The filing does not indicate status as a 10% owner.